Research progress of ICI and CAR-T in tumor immunotherapy.
- Author:
Meilin YUAN
1
;
Deqiao SHENG
2
;
Yi YANG
3
Author Information
1. Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, China Three Gorges University, Yichang 443002, China.
2. Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, China Three Gorges University, Yichang 443002, China. *Corresponding authors, E-mail: shengdq@ctgu.edu.cn.
3. Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, China Three Gorges University, Yichang 443002, China. *Corresponding authors, E-mail: yangyi1@ctgu.edu.cn.
- Publication Type:English Abstract
- MeSH:
Humans;
Neoplasms/immunology*;
Immune Checkpoint Inhibitors/therapeutic use*;
Receptors, Chimeric Antigen/genetics*;
Immunotherapy/methods*;
Immunotherapy, Adoptive/methods*;
Animals;
Cancer Vaccines/therapeutic use*
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(2):178-182
- CountryChina
- Language:Chinese
-
Abstract:
Tumor immunotherapy has revolutionized the treatment prospects for various malignant tumors. Immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell therapy (CAR-T) , as representative of tumor immunotherapy, have achieved tremendous success in clinical practice and have become the first-line clinical treatment options for certain tumors. This article summarizes the progress and challenges of immune checkpoint inhibitors and CAR-T therapy in tumor treatment, and discusses the future direction of tumor therapeutic vaccines development. Identifying novel therapeutic targets within the realm of tumor immunology, engineering innovative drug delivery systems, and employing combinatorial therapeutic strategies are poised to enhance therapeutic efficacy and patient outcomes in oncology, thereby extending benefits to a broader patient population.
